Mereo BioPharma Group Plc (MREO)
0.25
-0.02
(-8.16%)
USD |
NASDAQ |
Sep 04, 16:00
0.25
0.00 (0.00%)
Pre-Market: 20:00
Mereo BioPharma Group Research and Development Expense (Quarterly) : 1.811M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.811M |
| March 31, 2026 | 4.739M |
| December 31, 2025 | 4.187M |
| September 30, 2025 | 4.243M |
| June 30, 2025 | 5.440M |
| Date | Value |
|---|---|
| March 31, 2025 | 3.945M |
| December 31, 2024 | 8.739M |
| September 30, 2024 | 3.202M |
| June 30, 2024 | 4.952M |
| March 31, 2024 | 3.992M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | 3.020M |
| BioNTech SE | 514.38M |
| Silence Therapeutics Plc | 8.297M |
| Autolus Therapeutics Plc | 27.95M |